Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the worst malignancies in terms of prognosis, with an ever-increasing incidence in all highly developed countries. FOLFIRINOX and gemcitabine plus nab-paclitaxel (GnP) are both historical standard first-line regimens and, despite the effort to intensify first line treatment, the survival benefit is still marginal. The PAXG quadruplet (cisplatin, nabpaclitaxel, capecitabine, and gemcitabine) was developed to leverage taxane, fluoropyrimidine, and platinum synergy. PAXG demonstrated superior efficacy over GnP in a first line randomized phase 2 trial (PACT-19), and over FOLFIRINOX in nonmetastatic settings (PACT-21/CASSANDRA). However, comparative evidence between PAXG and FOLFIRINOX as first line treatment in the metastatic setting is lacking. Methods: This multicenter, retrospective study across 10 Italian oncological centers was conducted using a target trial emulation (TTE) framework. Eligible patients were aged 18-75 years with an ECOG performance status ≤1 and untreated mPDAC, who initiated first-line PAXG or (m)FOLFIRINOX between June 2011 and April 2025. Confounding was addressed via 1:1 propensity-score matching (PSM). The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), CA 19.9 response, and safety. Survival curves were estimated using Kaplan–Meier estimates and compared via log-rank tests. Hazard ratios (HRs) with 95% confidence intervals (CIs) were obtained from Cox proportional-hazards models clustered on matched pairs. Categorical endpoints were compared using Fisher’s exact test, with odds ratios calculated via cluster-robust logistic regression. Results: Of the 537 eligible patients, 402 were matched 1:1 into the final analytic cohort (n=201 per arm), achieving well-balanced baseline covariates. With a median overall follow-up of 43.4 months, PAXG significantly improved PFS compared with (m)FOLFIRINOX (median 8.3 vs. 6.8 months; HR 0.75, 95% CI 0.61–0.93; p=0.009) and improved OS (median 14.8 vs. 12.9 months; HR 0.80, 95% CI 0.65–0.99; p=0.044). Efficacy signals consistently favored PAXG in terms of ORR (52.3% vs. 40.6%; 3 p=0.043), DCR (85.8% vs. 71.4%; p=0.002), and CA 19.9 response (81.4% vs. 67.2%; p=0.021). Results were confirmed across sensitivity analyses. Conclusions: In this TTE, first-line PAXG was associated with statistically significant and clinically meaningful improvements in survival, and disease control compared with (m)FOLFIRINOX in patients with mPDAC. Alongside its efficacy and logistical benefits (single-day administration without central venous catheters), PAXG represents a valid first-line option outside of clinical trials and could provide a robust cytotoxic backbone for future integration with emerging targeted therapies, such as RAS inhibitors.

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the worst malignancies in terms of prognosis, with an ever-increasing incidence in all highly developed countries. FOLFIRINOX and gemcitabine plus nab-paclitaxel (GnP) are both historical standard first-line regimens and, despite the effort to intensify first line treatment, the survival benefit is still marginal. The PAXG quadruplet (cisplatin, nabpaclitaxel, capecitabine, and gemcitabine) was developed to leverage taxane, fluoropyrimidine, and platinum synergy. PAXG demonstrated superior efficacy over GnP in a first line randomized phase 2 trial (PACT-19), and over FOLFIRINOX in nonmetastatic settings (PACT-21/CASSANDRA). However, comparative evidence between PAXG and FOLFIRINOX as first line treatment in the metastatic setting is lacking. Methods: This multicenter, retrospective study across 10 Italian oncological centers was conducted using a target trial emulation (TTE) framework. Eligible patients were aged 18-75 years with an ECOG performance status ≤1 and untreated mPDAC, who initiated first-line PAXG or (m)FOLFIRINOX between June 2011 and April 2025. Confounding was addressed via 1:1 propensity-score matching (PSM). The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), CA 19.9 response, and safety. Survival curves were estimated using Kaplan–Meier estimates and compared via log-rank tests. Hazard ratios (HRs) with 95% confidence intervals (CIs) were obtained from Cox proportional-hazards models clustered on matched pairs. Categorical endpoints were compared using Fisher’s exact test, with odds ratios calculated via cluster-robust logistic regression. Results: Of the 537 eligible patients, 402 were matched 1:1 into the final analytic cohort (n=201 per arm), achieving well-balanced baseline covariates. With a median overall follow-up of 43.4 months, PAXG significantly improved PFS compared with (m)FOLFIRINOX (median 8.3 vs. 6.8 months; HR 0.75, 95% CI 0.61–0.93; p=0.009) and improved OS (median 14.8 vs. 12.9 months; HR 0.80, 95% CI 0.65–0.99; p=0.044). Efficacy signals consistently favored PAXG in terms of ORR (52.3% vs. 40.6%; 3 p=0.043), DCR (85.8% vs. 71.4%; p=0.002), and CA 19.9 response (81.4% vs. 67.2%; p=0.021). Results were confirmed across sensitivity analyses. Conclusions: In this TTE, first-line PAXG was associated with statistically significant and clinically meaningful improvements in survival, and disease control compared with (m)FOLFIRINOX in patients with mPDAC. Alongside its efficacy and logistical benefits (single-day administration without central venous catheters), PAXG represents a valid first-line option outside of clinical trials and could provide a robust cytotoxic backbone for future integration with emerging targeted therapies, such as RAS inhibitors.

PAXG vs FOLFIRINOX: Comparative Clinical Outcomes of Intensive Polychemotherapy Regimens as First-Line Treatment for Metastatic Pancreatic Cancer

DI PAOLO, GIACOMO
2024/2025

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the worst malignancies in terms of prognosis, with an ever-increasing incidence in all highly developed countries. FOLFIRINOX and gemcitabine plus nab-paclitaxel (GnP) are both historical standard first-line regimens and, despite the effort to intensify first line treatment, the survival benefit is still marginal. The PAXG quadruplet (cisplatin, nabpaclitaxel, capecitabine, and gemcitabine) was developed to leverage taxane, fluoropyrimidine, and platinum synergy. PAXG demonstrated superior efficacy over GnP in a first line randomized phase 2 trial (PACT-19), and over FOLFIRINOX in nonmetastatic settings (PACT-21/CASSANDRA). However, comparative evidence between PAXG and FOLFIRINOX as first line treatment in the metastatic setting is lacking. Methods: This multicenter, retrospective study across 10 Italian oncological centers was conducted using a target trial emulation (TTE) framework. Eligible patients were aged 18-75 years with an ECOG performance status ≤1 and untreated mPDAC, who initiated first-line PAXG or (m)FOLFIRINOX between June 2011 and April 2025. Confounding was addressed via 1:1 propensity-score matching (PSM). The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), CA 19.9 response, and safety. Survival curves were estimated using Kaplan–Meier estimates and compared via log-rank tests. Hazard ratios (HRs) with 95% confidence intervals (CIs) were obtained from Cox proportional-hazards models clustered on matched pairs. Categorical endpoints were compared using Fisher’s exact test, with odds ratios calculated via cluster-robust logistic regression. Results: Of the 537 eligible patients, 402 were matched 1:1 into the final analytic cohort (n=201 per arm), achieving well-balanced baseline covariates. With a median overall follow-up of 43.4 months, PAXG significantly improved PFS compared with (m)FOLFIRINOX (median 8.3 vs. 6.8 months; HR 0.75, 95% CI 0.61–0.93; p=0.009) and improved OS (median 14.8 vs. 12.9 months; HR 0.80, 95% CI 0.65–0.99; p=0.044). Efficacy signals consistently favored PAXG in terms of ORR (52.3% vs. 40.6%; 3 p=0.043), DCR (85.8% vs. 71.4%; p=0.002), and CA 19.9 response (81.4% vs. 67.2%; p=0.021). Results were confirmed across sensitivity analyses. Conclusions: In this TTE, first-line PAXG was associated with statistically significant and clinically meaningful improvements in survival, and disease control compared with (m)FOLFIRINOX in patients with mPDAC. Alongside its efficacy and logistical benefits (single-day administration without central venous catheters), PAXG represents a valid first-line option outside of clinical trials and could provide a robust cytotoxic backbone for future integration with emerging targeted therapies, such as RAS inhibitors.
2024
PAXG vs FOLFIRINOX: Comparative Clinical Outcomes of Intensive Polychemotherapy Regimens as First-Line Treatment for Metastatic Pancreatic Cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the worst malignancies in terms of prognosis, with an ever-increasing incidence in all highly developed countries. FOLFIRINOX and gemcitabine plus nab-paclitaxel (GnP) are both historical standard first-line regimens and, despite the effort to intensify first line treatment, the survival benefit is still marginal. The PAXG quadruplet (cisplatin, nabpaclitaxel, capecitabine, and gemcitabine) was developed to leverage taxane, fluoropyrimidine, and platinum synergy. PAXG demonstrated superior efficacy over GnP in a first line randomized phase 2 trial (PACT-19), and over FOLFIRINOX in nonmetastatic settings (PACT-21/CASSANDRA). However, comparative evidence between PAXG and FOLFIRINOX as first line treatment in the metastatic setting is lacking. Methods: This multicenter, retrospective study across 10 Italian oncological centers was conducted using a target trial emulation (TTE) framework. Eligible patients were aged 18-75 years with an ECOG performance status ≤1 and untreated mPDAC, who initiated first-line PAXG or (m)FOLFIRINOX between June 2011 and April 2025. Confounding was addressed via 1:1 propensity-score matching (PSM). The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), CA 19.9 response, and safety. Survival curves were estimated using Kaplan–Meier estimates and compared via log-rank tests. Hazard ratios (HRs) with 95% confidence intervals (CIs) were obtained from Cox proportional-hazards models clustered on matched pairs. Categorical endpoints were compared using Fisher’s exact test, with odds ratios calculated via cluster-robust logistic regression. Results: Of the 537 eligible patients, 402 were matched 1:1 into the final analytic cohort (n=201 per arm), achieving well-balanced baseline covariates. With a median overall follow-up of 43.4 months, PAXG significantly improved PFS compared with (m)FOLFIRINOX (median 8.3 vs. 6.8 months; HR 0.75, 95% CI 0.61–0.93; p=0.009) and improved OS (median 14.8 vs. 12.9 months; HR 0.80, 95% CI 0.65–0.99; p=0.044). Efficacy signals consistently favored PAXG in terms of ORR (52.3% vs. 40.6%; 3 p=0.043), DCR (85.8% vs. 71.4%; p=0.002), and CA 19.9 response (81.4% vs. 67.2%; p=0.021). Results were confirmed across sensitivity analyses. Conclusions: In this TTE, first-line PAXG was associated with statistically significant and clinically meaningful improvements in survival, and disease control compared with (m)FOLFIRINOX in patients with mPDAC. Alongside its efficacy and logistical benefits (single-day administration without central venous catheters), PAXG represents a valid first-line option outside of clinical trials and could provide a robust cytotoxic backbone for future integration with emerging targeted therapies, such as RAS inhibitors.
pancreatic cancer
PAXG
FOLFIRINOX
OS
PFS
File in questo prodotto:
File Dimensione Formato  
DiPaolo_Giacomo.pdf

Accesso riservato

Dimensione 1.58 MB
Formato Adobe PDF
1.58 MB Adobe PDF

The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12608/119672